Population Pharmacokinetic Modeling and Exposure Assessment for Doxycycline in Chinese Pediatric Patients with Severe Refractory Mycoplasma pneumoniae Pneumonia
Pharmaceutics · 15.11.2026 · 18 (11) · 1477
DOI: 10.3390/pharmaceutics18111477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.11.2026. Verfasst von Meng Lv und 8 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Scientific and Technological Project in Henan Province, Zhengzhou Medical Research Project, Henan Province Clinical Research Center for Pediatric Diseases.
Abstract (Originalsprache)
Objectives
Severe refractory Mycoplasma pneumoniae pneumonia (SRMPP) remains a significant threat to pediatric patients. Doxycycline is recommended as an alternative treatment for pediatric SRMPP, while its pharmacokinetic (PK) profile in this specific population is still poorly characterized. This study aimed to characterize the PK profile of intravenous doxycycline by developing a population pharmacokinetic (PopPK) model in Chinese pediatric patients with SRMPP and to evaluate its exposure across different age groups.
Methods
The residual blood samples were prospectively collected from patients aged ≤ 18 years receiving intravenous doxycycline for the treatment of SRMPP between April 2023 and April 2025 at the Children’s Hospital Affiliated to Zhengzhou University using the opportunistic sampling approach. Plasma concentrations of doxycycline were determined by high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS) and PopPK analysis was performed with the Phoenix NLME software. The steady-state areas under the concentration–time curve from 0 to 24 h (AUCss,0–24 h) of doxycycline were calculated based on Monte Carlo simulation results and compared between groups by geometric mean ratios (GMRs) with 90% confidence intervals (90% CIs).
Results
A total of 81 doxycycline plasma concentrations from 68 pediatric patients aged 1.8 to 13.2 years with SRMPP receiving intravenous doxycycline were collected and included for the final PopPK analysis. A one-compartment PopPK model with first-order elimination best described the current data. Body weight was incorporated as the a priori covariate using allometric scaling (fixed exponents of 0.75 for CL and 1.0 for V) and no other screened covariates were identified to have a significant impact on CL or V. For the final model, the estimated typical values were 5.08 L/h/70 kg for CL and 56.57 L/70 kg for V, respectively. Using the 2 to
Förderung
- Medical Scientific and Technological Project in Henan Province
- Zhengzhou Medical Research Project
- Henan Province Clinical Research Center for Pediatric Diseases
Zitieren
APA
Lv, M., Zhou, Y., Xu, S., Su, Y., Tang, Y., Zhang, S., Chang, Z., Xie, F., & Tao, X. (2026). Population Pharmacokinetic Modeling and Exposure Assessment for Doxycycline in Chinese Pediatric Patients with Severe Refractory Mycoplasma pneumoniae Pneumonia. Pharmaceutics, 18(11), 1477. https://doi.org/10.3390/pharmaceutics18111477
Vancouver
Lv M, Zhou Y, Xu S, Su Y, Tang Y, Zhang S, et al. Population Pharmacokinetic Modeling and Exposure Assessment for Doxycycline in Chinese Pediatric Patients with Severe Refractory Mycoplasma pneumoniae Pneumonia. Pharmaceutics. 2026;18(11):1477. doi:10.3390/pharmaceutics18111477
BibTeX
@article{Lv2026,
author = {Lv, Meng and Zhou, Yuxue and Xu, Shasha and Su, Yanyan and Tang, Yu and Zhang, Shengnan and Chang, Zhao and Xie, Feifan and Tao, Xingru},
title = {Population Pharmacokinetic Modeling and Exposure Assessment for Doxycycline in Chinese Pediatric Patients with Severe Refractory Mycoplasma pneumoniae Pneumonia},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1477},
doi = {10.3390/pharmaceutics18111477}
}
EUVIMED